- Colorectal cancer can be severely challenging to treat as it begins to spread.
- Researchers are still seeking to develop effective treatments for colorectal cancer.
- Data from a phase 3 study revealed that treatment with fruquintinib is superior to placebo in treating metastatic colorectal cancer.
Colorectal cancer is a type of cancer that can be very dangerous when it spreads.
A recent
Researchers found that the drug fruquintinib was superior to the placebo in treatment outcomes. The results indicate that fruquintinib may help survival among individuals with refractory metastatic colorectal cancer.
This study expands research into the treatment of refractory metastatic colorectal cancer, which is colorectal cancer that has spread and is difficult to control or treat.
The study was an international, randomized, double-blind, placebo-controlled, phase 3 study. This type of study allows for valuable data collection with a low risk of bias. The study included data from participants in 14 countries, a total of 691 participants. All participants had already received previous treatment for colorectal cancer.
The researchers divided participants into two groups. One group received a placebo, and the other received fruquintinib, a medication that influences cell growth.
Dr. Wael Harb, a hematologist and medical oncologist at MemorialCare Cancer Institute at Orange Coast Medical Center in Fountain Valley, California, and vice president of Medical Affairs at Syneos Health, who was not involved in the study, explained that fruquintinib is “a selective inhibitor of vascular endothelial growth factor (VEGF) receptors, works by essentially depriving the tumor of its blood supply, thus impeding its growth and spread.”
Participants…
Read the full article here